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Summary
In persons with haemophilia (PWH), repeated ankle haemarthroses lead to pain, loss of joint range 
of motion (ROM), and limitations in activity and participation in society. PWH are offered ankle 
arthrodesis (AA) to eliminate pain. In our experience, PWH are hesitant to proceed to AA due to 
concerns regarding gait anomalies, functional decline and complete loss of ROM. The aim of this 
study was to report outcomes in ROM, assistive device (AD)/wheelchair use, activity scale and 
work/school absenteeism for participants in the CDC’s Universal Data Collection surveillance 
project (UDC) pre- and post- AA. Males with haemophilia enrolled in the UDC with first report of 
AA (1998–2010) were selected. Descriptive statistics were calculated using data from the annual 
study visit pre-AA and the follow-up visit (~12–24 months) post-AA. The 68 subjects who 
fulfilled the criteria were: mean age 36.9 years (SD = 12.9); 85.3% white; 85.3% haemophilia A; 
72% severe, 20.6% moderate; and 10.3% with inhibitor once during the study period. Mean loss in 
total arc of ankle motion was 17.02° (SD = 21.8, P ≤ 0.01) pre- compared to post-AA. For 61.8%, 
there was no change in use of AD for ambulation/mobility. For 85.3%, there was no change in use 
of a wheelchair. On a self-reported activity scale, 11.8% improved, 8.8% worsened and 79.4% did 
not change. Work/school absenteeism averaged 2.7 (SD = 6.4) pre- and 1.5 (SD = 6.4, P = 0.26) 
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days per year post-AA. While ankle ROM was significantly reduced post-AA, for most subjects, 
there was no change in use of AD/wheelchair for ambulation/mobility. Physical activity was 
maintained and work/school absenteeism remained stable.
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Introduction
Bleeding into joints and muscles is the most common clinical manifestation of haemophilia, 
with approximately 80–85% of bleeding episodes occurring in the joints [1–3]; the ankle is 
more commonly affected in the first 5 years, while the knee and elbow are more commonly 
affected thereafter [3]. In a randomized controlled trial of prophylaxis vs. enhanced episodic 
factor replacement therapy, Manco-Johnson et al. [4] found 18 abnormal joints in 15 of 65 
children enrolled, all under the age of 6 years. Of the 15 children, 2 were on prophylaxis and 
13 were on the episodic treatment arm. Thirteen of the 18 joints found to be abnormal by 
MRI or X-ray, were in the ankle joints. Despite prophylaxis or aggressive factor 
replacement, we have observed that persons with haemophilia (PWH) continue to be at risk 
for joint arthropathy. Advanced stage haemophilic arthropathy, due to repeated joint 
haemarthroses, is characterized by pain, joint range of motion (ROM) loss, strength loss and 
deformity, culminating in loss of mobility [1–3].
Surgical ankle arthrodesis (AA) or ankle fusion to eliminate ROM at the fused joint has been 
the preferred procedure for painful end-stage haemophilic arthropathy (Grade IV – Modified 
Arnold-Hilgartner classification of haemophilic arthropathy) in this joint [5]. Reported 
indications for AA include severe pain, recurrent haemarthrosis, chronic synovitis, equinus 
contracture, extensive joint incongruence, or loss of ability to walk [6,7]. Despite reports of 
effective surgical outcomes in reducing pain, eliminating further haemarthroses and 
correcting deformity [6–9], in our clinical experience, PWH are reluctant to undergo AA, 
reporting fear of loss of all ankle motion and becoming more limited in physical activity. 
PWH often postpone the procedure until pain becomes incapacitating. End-stage 
haemophilic arthropathy often results in loss of quality of life and disability [3,10].
The literature contains few reports of functional outcomes related to AA in PWH. Existing 
studies are largely limited to case reports and primarily include outcomes related to surgical 
procedures such as successful joint fusion rates, infection rates, pain and joint haemarthroses 
recurrence [6–9].
The purpose of this study was to report selected outcomes available through the Center for 
Disease Control and Prevention’s (CDC) Universal Data Collection (UDC) project in PWH 
who have undergone AA from 1998 to 2010. Surveillance data from the UDC were used to 
describe changes in ankle joint ROM and physical functioning [use of an assistive device 
(AD) and/or wheelchair for mobility, self-reported activity level and absenteeism from 
work/school] as a result of AA. Patient characteristics and joint infection were also reported. 
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Pain, an important AA outcome, was not collected in the UDC and therefore is not available 
for analysis.
Materials and methods
From 1998 to 2010, data were collected at ~130 federally funded haemophilia treatment 
centres (HTCs) as part of the CDC-funded UDC. This project has been described elsewhere 
[11]. Each participating HTC and the CDC provided institutional review board oversight. 
Data were collected annually from participants, typically during comprehensive clinic visits.
A subset of UDC data fitting the inclusion and exclusion criteria was created for the analysis 
reported here. Male subjects with factor VIII or IX deficiency, who reported undergoing AA 
at least 1 year after enrolling in the UDC and had completed at least one UDC follow-up 
visit post-AA report, were included. This study was limited to subjects with first report of 
AA. Data were analysed from two annual UDC visits: (i) visit immediately prior to report of 
AA and (ii) the next follow-up visit post-AA (Fig. 1). This approach allowed for at least 9–
12 months of recovery post-AA.
The initial report of AA, when first performed, was included in the analysis. In a few cases 
of bilateral AA, only information about the first AA was analysed.
Measures
Outcomes of interest included change in measured ankle ROM and self-reported use of an 
AD (cane, crutches or walker), use of a wheelchair, activity level and number of days 
missed from work/school due to lower extremity problems. Presence of a physician-
diagnosed joint infection in any joint in the year preceding follow-up visits was included.
Ankle dorsiflexion (DF) and plantarflexion (PF) ROM was measured, as described by 
Norkin and White [12], by a physical therapist (PT) or a trained medical provider using a 
standard goniometer and passively moving the ankle to its full extent, recording the 
measurement to the nearest degree. Using the same methods described by Norkin and White 
[12], Soucie et al. [13] found ≤5° difference among nine licensed PTs on a subset of 10 
individuals. Ankle ROM values in otherwise healthy 20- to 44-year-old males were 12.7° 
(SD 11.6–13.8) DF and 54.6° (SD 53.2–56.0) PF [13].
Use of an AD or wheelchair since the last annual HTC visit was recorded as ‘never’, 
‘intermittent’ or ‘always’. Self-reported activity level at time of HTC visit was recorded by 
presenting the patient with five choices, on a Likert-like scale, that best described their 
overall activity level and ranged from ‘requiring assistance for self-care’ representing ‘most 
limited’, to ‘unrestricted work/school and recreational activities’ representing ‘least limited’. 
In UDC, self-reported absenteeism from work/school was recorded as number of days 
missed since the last annual HTC visit. Physician-diagnosed joint infection, in any joint in 
the previous year, was recorded as a yes/no variable.
For analysis, categories were created within existing UDC variables: for use of an AD or 
wheelchair, ‘intermittent’ and ‘always’ categories were merged. This categorization 
improved statistical stability of the test statistics that were otherwise unstable and less 
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reliable. For example, cross-tabulations of pre- and post-AA wheelchair and AD usage as 
three level variables resulted in more than 50% of the cells having ‘expected’ values less 
than 5 that made the chi-square test questionable. Additionally, the stated categorization 
provided a two-group variable that reflected ‘no usage’ vs. ‘any usage’. However, for 
interested readers, a description of movement of people to and from the ‘intermittent’ usage 
category is provided in the results for qualitative/clinical assessment. For the self-reported 
activity scale, a dichotomous variable, representing high and low activity levels, was created 
by merging the top two ‘least’ limited and the remaining three ‘more’ limited options 
respectively; for absenteeism from work/school since their previous HTC visit, mean 
number of days missed pre- and post-AA and ‘none’ vs. ‘at least’ 1 day missed were 
evaluated.
Covariates of interest included age at AA, race, ethnicity, body mass index (BMI), 
haemophilia type and severity, presence of factor replacement therapy inhibitor, and history 
of target joint (per UDC definition, ≥4 bleeds in a 6-month period) or invasive procedures 
performed on any other joint.
Subjects’ age in years at AA was estimated by subtracting birth date from visit date of 
reported AA, with differences rounded to the highest complete year. Self-reported patient 
race was recorded per U.S. census categories, including Hispanic/non-Hispanic ethnicity.
Body mass index was calculated at each visit. Based on BMI, each subject was categorized 
according to the year 2000 CDC U.S. Growth Charts [14] as being obese, overweight or 
normal and defined as weighing above the 95th, within the 85th–95th, and below the 85th 
percentile for gender and age respectively. BMI data, collected at the time of follow-up visit 
post-AA report, were analysed in the multivariate model.
Haemophilia type was documented as either ‘A’ or ‘B’ depending on the deficient clotting 
factor (VIII or IX respectively). The site of the first bleed was recorded. Haemophilia 
severity was noted and expressed as a per cent of normally expected factor activity level and 
categorized as severe (<1%), moderate (≥1% to 5%) or mild (>5% to <50%).
Factor inhibitor antibodies were categorized as either positive (patient had at least one 
recorded inhibitor titre of ≥0.5 Bethesda units) or negative. Participants with no recorded 
antibody measurements were assumed to be negative.
We adjusted for the possible effect of previous history of, or current joint arthropathy, in our 
multivariate regression model by creating a dichotomous variable. Subjects who reported a 
target joint or any invasive orthopaedic procedure on any major joint other than the ankle 
(shoulder, elbow, hip or knee) at any annual visit before reporting AA were coded ‘positive’ 
with others coded ‘negative’.
Statistical analysis
Frequency distributions of select demographic and clinical variables at baseline were 
calculated. Ankle joint ROM measurements pre- and post-AA were summarized. ROM 
means were computed for PF, DF and the complete arc, and were calculated separately for 
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right and left ankles. Statistical tests of significance (paired t-test) were done to identify 
significant changes in mean ROM post-AA. Frequency distribution of changes in functional 
outcomes post-AA was performed. Because of small cell frequencies, statistical tests of 
significance were not done and the results are reported as frequencies. All analyses were 
performed in SAS® software version 9 (SAS Institute Inc., Cary, NC, USA). Generalized 
linear model (GLM) is a generalization of ordinary linear regression, proposed by Nelder 
and Wedderburn [15] that can accommodate response variables with non-normal 
distribution.
To give readers some sense of the independent associations between various characteristics 
of interest and the outcome; a single multivariate GLM without formal model building steps 
was used. We deliberately refrained from formal multivariate GLM modelling and analysis 
for several reasons – the total sample size was small (n = 51); only one variable attained 
statistical significance in univariate analysis; and the outcome variable showed considerably 
large variations (overall mean change in ROM −17.02, SD 21.8). These factors would have 
resulted in unpredictable model building and an unstable multivariate model.
Results
Between June 1998 and September 2010, 150 individuals with haemophilia who underwent 
AA were identified in UDC data. After excluding individuals who underwent AA prior to 
their first UDC visit and those who had not had at least 2 post-AA follow-up visits, 68 
subjects were included.
The mean age at AA was 36.9 (SD 12.9) years. The majority (58, 85.3%) of the study 
subjects were white, with four (8.8%) reported as Hispanic. Fifty-eight (85.3%) had 
haemophilia A, 49 (72.1%) had severe at least once during the study period. Most 
individuals were diagnosed with haemophilia early in life, with 27 (39.7%) diagnosed prior 
to their first birthday (mean 14.9 months, SD 31.5 months). Most subjects experienced their 
first bleed at an early age (mean 18 months, SD 33.9 months). Table 1 includes the 
distribution of these and other demographic and clinical characteristics.
Statistically significant reductions in mean joint ROM post-AA for all measurements were 
observed. Overall, a reduction of 17.02° was observed in the complete arc of ankle motion 
post-AA, of which 13.12° (77%) of the total reduction was seen in PF and 3.9° (23%) in DF 
(Table 2). Post-AA, remaining PF and DF averaged 14.57° (SD = 15.01) and −1.63° (SD = 
7.17) respectively. Most observed reductions in ROM measurements were statistically 
significantly different from zero (Table 3).
Functional outcomes (AD use, wheelchair use, activity level, missed days from work/
school) and reported occurrence of physician-diagnosed joint infection are summarized in 
Table 4. Forty-two (61.8%) individuals reported no change in use of an AD for mobility, 23 
(55%) of which did not use an AD pre- or post-AA. Fifty-eight (85.3%) subjects reported no 
change in use of a wheelchair with 57 (98%, 90% of the total) reporting no use of a 
wheelchair pre- or post-AA. Analysis taking movements across the three categories of 
wheelchair/AD use showed that four ‘intermittent’ wheelchair users and one ‘always’ 
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wheelchair user stopped using the wheelchair altogether. Another five individuals who did 
not use a wheelchair pre-AA started using it ‘intermittently’ post-AA. None of the non-
wheelchair users moved to ‘always’ a use wheelchair user post-AA. A somewhat similar 
pattern was observed in terms of use of AD. Two ‘always’ and 11 ‘intermittent’ users 
stopped using ADs altogether post-AA and two ‘always’ AD users became ‘intermittent’ 
users. On the other hand, 13 non-AD users became intermittent users. None of the non-AD 
users moved to the always use category. Small numbers prevented evaluation by formal 
statistical tests of significance and the data are presented to allow readers qualitative/clinical 
assessment of the impact of AA on pre- and post-AA wheelchair/AD use.
Fifty-four subjects reported no change in activity level post-AA [8 (11.8%) improved and 6 
(8.8%) declined]. Seventeen (35%) subjects who reported missing at least one work/school 
day pre-AA reported not missing any post-AA, and seven (10.3%) first missed work/school 
post-AA. Days missed averaged 2.7 (SD 6.4) before and 1.5 (6.4) post-AA (P = 0.3). Two 
(2.9%) subjects experienced at least one joint infection (unspecified location) during the 2 
years post-AA.
Bivariate comparisons were used to identify significant demographic or clinical 
characteristics (Table 5) associated with loss in joint ROM post-AA. These analyses showed 
no statistical significance except haemophilia severity, which was significantly associated 
with ROM loss. Age at assessment reached marginal significance (P = 0.06). Formal 
multivariate analysis was not carried out for reasons stated earlier. However, to give the 
readers a glimpse of what a multivariate adjusted model from the data would look like, we 
evaluated all variables we considered biologically relevant (based on contemporary 
literature and authors’ experience) and those with a P-value of 0.02 or less in univariate 
assessment, in a single multivariate GLM model, without going through formal steps of 
multivariate model building. The multivariate model consisted of the following variables: 
age at AA, ethnicity, BMI, type and severity of haemophilia, presence of factor inhibitors 
and history of target joints or invasive orthopaedic procedures (Table 5). After adjusting for 
other variables in the model (stated above), individuals younger than 25 years experienced a 
larger reduction in joint ROM than subjects 35 year or older (−20.09°, SD 8.49°, P = 0.02). 
However, overall, the age variable was only marginally statistically significant (P = 0.06) 
and did not reach the cut-off of 0.05 for consideration as statistically significant. People with 
mild and moderate haemophilia experienced greater loss in joint ROM than people with 
severe haemophilia (mild −18.35°, SD 14.21, P = 0.2; moderate −20.82°, SD 7.73°, P = 
0.01). Haemophilia severity was also found to be statistically significant overall (P = 0.02). 
No other statistically significant associations were found.
Discussion
The 68 individuals with haemophilia studied had a mean age at first AA of 36.9 years, 
similar to previous reports (mean age range of 25–41.8 years) [6–9]. Overall, functional 
outcomes did not change. This should reassure patients about proceeding with AA when the 
indication for it is firm.
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Ankle arthrodesis aims to eliminate ROM of the involved joint in painful end-stage 
haemophilic arthropathy. We expected subjects to exhibit loss in ROM, but not total loss as 
ankle ROM encompasses multiple joints. There was a significant reduction in mean joint 
ROM of the ankle, resulting in loss of arc of motion of 17.02° (23% decrease in DF; 77% 
decrease in PF). The type of AA and joints involved may influence changes in ROM [6–9]. 
Haemophilia-related pre- and post- AA ROM data in degrees have not been reported 
previously. In the non-haemophilia literature, Gellman et al. [16], via in vitro analysis, 
reported varying percentage losses in DF (50–62.8%) and PF (70.3–82.2%) depending on 
the type of AA. Data on the type of AA were not collected in the UDC. Single, double, and 
triple AA may have been included in the analysis and potentially contributed to the 
relatively large SD for ROM loss.
Age and severity of haemophilia were the only characteristics significantly associated with 
joint ROM loss following AA. The type of AA performed is probably the biggest factor in 
the amount of loss in ankle ROM in PWH and demographic or clinical characteristics most 
likely only minimally influence this change. Our finding that age and severity were 
significant factors in influencing change in ROM was somewhat surprising; however, data 
from previously published studies may provide an explanation. First, persons with more 
severe haemophilia, due to more severe joint disease, have greater limitations in ROM prior 
to arthrodesis [17]. Second, healthy individuals without haemophilia have decreased ankle 
joint ROM with increasing age [13]. In this study, individuals less than 25 years and/or with 
moderate haemophilia experienced greater ROM loss compared to those older than 35 years 
and/or with severe haemophilia respectively. Thus, prior to arthrodesis, younger and/or 
persons with less severe haemophilia had more available joint ROM that could be lost 
following surgery, as compared to older and/or persons with more severe haemophilia. The 
average total ROM recorded prior to AA was 39.3°, 33.0° and 25.21° for persons younger 
than 25, 25–34 and 35 years or older, respectively, and 50.0°, 43.55° and 24.30° for people 
with mild, moderate and severe haemophilia respectively.
Individuals in this study did not experience an overall change in AD or wheelchair use pre-
and post-AA. The lack of overall change in AD use is not altogether surprising as PWH 
commonly have more than one joint involved. If the AD was used to address a problem with 
a joint other than the ankle, we expect no change. We anticipated our findings to be 
consistent with reports from the contemporary literature. Gamble et al. [6] reported 
wheelchair use in four of eight individuals pre-AA; three of four discontinued wheelchair 
use post-AA, and the fourth, due to severe pain in the knee, required continued use of the 
wheelchair. Panatopoulos et al. [7] reported on four individuals in whom walking improved 
and AD use became unnecessary in all individuals. The UDC does not link use of AD with a 
specific joint or disability. It is plausible the people started AD use post-AA for reasons 
unrelated to AA.
In this study, the average number of days missed from work/school, since the last annual 
visit, went from 2.7 to 1.5 days pre- vs. post-AA. This change represented a nearly 45% 
reduction in days missed post-AA. Due to the small sample size, the difference did not attain 
statistical significance. These results are consistent with observations within the authors’ 
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respective institutions. If the ankle is the primary issue limiting participation in school/work, 
post-AA, this outcome is improved.
Two (2.9%) subjects experienced a physician-diagnosed infection in the 2-year follow-up 
period. Because the UDC does not collect data indicating the infected joint, the site is 
unspecified and a 0–2.9% rate of infection is possible for this cohort. In the haemophilia AA 
literature, during a mean follow-up of 2.7–9.4 years, an infection rate of 0–5% was reported 
[6–9,18].
We recognize the small sample size and thus the resultant low power as a limitation of this 
study. Nonetheless, given the relative scarcity of longitudinal data on PWH who have 
undergone AA, we consider our results informative. We applied a strict set of criteria in 
defining an analytic dataset from the larger UDC data to ensure inclusion only of individuals 
with complete and unambiguous information available. Therefore, while our results did not 
attain statistical significance, we expect the results reported here to be valid and unbiased. 
We were able to show some large differences that are considered significant in a clinical 
sense, despite being unable to attain the desired 0.05 P-value. Most subjects reported 
maintenance or improved functional outcomes. Despite consistent report of reduction in pain 
post-AA [6–9], lack of pain data is considered a limitation of this study, as it is the primary 
reason PWH consider AA. We caution our readers to consider the limitations stated earlier, 
when attempting to draw inferences from the multivariate model.
Conclusion
Ankle arthrodesis resulted in significant ankle joint ROM loss, but not complete loss, for 
both DF and PF among these UDC subjects in the ~12–24 month period, post-AA. Persons 
under 25 years or with moderate haemophilia experienced the largest loss in arc of motion 
compared to persons over 35 years or with severe haemophilia. PWH commonly perceive 
AA as a debilitating procedure that results in functional decline. Despite loss in ankle ROM, 
the aim of AA, selected UDC functional outcomes were no worse post-AA. Though this 
study reports relatively short-term outcomes, the results may provide reassurance to PWH 
who are reluctant to undergo this procedure. Though pain was not included as an outcome in 
the UDC, previous studies [8,9] strongly support the efficacy of AA in reducing pain. It is 
likely that pain was also reduced in this cohort. In counselling PWH, the type of procedure, 
the presence of additional lower extremity haemophilic arthropathies, and patient-desired 
goals, all need to be considered when discussing individual patient expectations post-AA. 
The less than optimal statistical power and the short-term nature of the data in this study 
both point to the need for additional research on this subject.
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Fig. 1. 
Graphic presentation of UDC visits timeline, highlighting time of ankle arthrodesis (AA) 
and the UDC visits selected for data analysis.
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Table 1
Demographic and clinical characteristics of males with haemophilia undergoing ankle arthrodesis.
Characteristic n(%)
Age at diagnosis (months)
 <1 27 (39.7)
 1–6 13 (19.1)
 6–11 10 (14.7)
 12+ 18 (26.5)
Age at ankle arthrodesis (years)
 ≤24 15 (22.1)
 25–34 13 (19.1)
 35–44 20 (29.4)
 45+ 20 (29.4)
Age in months at first bleed (n = 51)*
 <1 14 (27.5)
 1–6 7 (13.7)
 6–11 12 (23.5)
 12+ 18 (35.3)
Site of first bleed (n = 48)*
 Head (intra or extra cranial) 3 (<0.1)
 Oral mucosa 3 (<0.1)
 Circumcision 14 (0.2)
 Joint 8 (0.1)
 Others 20 (0.4)
Race
 White 58 (85.2)
 All minorities 10 (14.8)
Type of haemophilia
 Haemophilia A 58 (85.3)
 Haemophilia B 10 (14.7)
Haemophilia severity
 Mild 5 (7.3)
 Moderate 14 (20.6)
 Severe 49 (72.1)
Factor inhibitors (ever)
 Positive 7 (10.3)
 Negative 61 (89.7)
History of target joints or an invasive procedure in other joints
 Yes 46 (32.35)
 No 22 (67.65)
Body mass index at arthrodesis
 Underweight 2 (2.9)
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Characteristic n(%)
 Normal 20 (29.4)
 Overweight 26 (38.2)
 Obese 20 (29.4)
*
n of <68 due to missing data.
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Table 2
Comparison of average range of motion (degrees) of the ankle joint pre- and post-ankle arthrodesis.
Plane of motion
Before arthrodesis (n = 51)*
Mean (STD)
After arthrodesis (n = 51)*
Mean (STD)
Complete arc 29.96 (20.89) 12.94 (15.5)
Dorsiflexion 2.27 (9.85) −1.63 (7.17)
Plantarflexion 27.69 (17.6) 14.57 (15.01)
Left ankle (n = 29) Right ankle (n = 22) Left ankle (n = 29) Right ankle (n = 22)
Complete arc 28.76 (19.45) 31.55 (23.04) 16.93 (16.95) 7.68 (11.73)
Dorsiflexion 0.28 (10.66) 4.91 (8.17) −2.83 (8.42) −0.05 (4.84)
Plantarflexion 28.48 (18.07) 26.64 (17.33) 19.76 (16.22) 7.73 (9.96)
*Comparisons restricted to patient with complete set of measurements available (pre- and post-ankle arthrodesis).
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Table 3
Average change in range of motion (degrees) of the ankle joint pre- and post-ankle arthrodesis.
Mean (SE) change in ROM P-value*
Overall Complete arc −17.02 (3.05) <0.01
Dorsiflexion −3.9 (1.42) <0.01
Plantarflexion −13.12 (2.73) <0.01
Left Complete arc −11.83 (3.34) <0.01
Dorsiflexion −3.10 (2.12) 0.15
Plantarflexion −8.72 (3.45) 0.02
Right Complete arc −23.86 (5.28) <0.01
Dorsiflexion −4.95 (1.75) 0.01
Plantarflexion −18.91 (4.16) <0.01
*
Test that change is not different than zero.
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Table 4
Changes in physical functioning and joint infection outcomes post-ankle arthrodesis.
Outcome n(%)
Use of assistive device for ambulation/mobility
 Stopped using after fusion 13 (19.1)
 Started using after fusion 13 (19.1)
 No change 42 (61.8)
Use of a wheelchair for mobility
 Stopped using after fusion 5 (7.4)
 Started using after fusion 5 (7.4)
 No change 58 (85.3)
Activity level
 Improved after fusion 8 (11.8)
 Got worse after fusion 6 (8.8)
 No change 54 (79.4)
Missed at least one day from work/school
 No days missed after fusion (improved) 17 (25)
 Missed for the first time after fusion (worse) 7 (10.3)
 No change 44 (64.7)
Average number of work/school days missed Mean (SD)
 Before arthrodesis 2.7 (6.4)
 After arthrodesis 1.5 (6.4)
Joint infections
 Repeat experience after fusion 0 (0.0)
 First experienced after fusion 2 (2.9)
 No change 66 (97.1)
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Table 5
Multivariate GLM analysis of the effect of characteristics of interest on the drop in overall range of motion on 
ankle joint post-ankle arthrodesis (F = 1.73, P = 0.11).
Characteristic Parameter estimate Standard error P
Age at procedure
 <25 −20.09 8.49 0.02
 25–34 −8.95 7.32 0.23
 ≥35 Reference
Race
 Minorities −2.68 8.96 0.77
 White Reference
BMI
 Obese −4.55 15.64 0.77
 Overweight −11.01 16.10 0.50
 Normal −7.11 16.47 0.67
 Underweight Reference
Type of haemophilia
 Haemophilia A −3.53 8.35 0.67
 Haemophilia B Reference
Haemophilia severity
 Moderate −20.82 7.73 0.01
 Mild −18.35 14.21 0.20
 Severe Reference
Inhibitors
 Positive −8.27 9.97 0.41
 Negative Reference
History of target joints or invasive orthopaedic procedures
 No −1.46 7.02 0.84
 Yes Reference
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